Effect of narrowband ultraviolet B therapy on serum levels of CD26/dipeptidyl-peptidase IV and truncated form of substance P in plaque-type psoriasis

Not Applicable

Completed

• Conditions: itch in psoriasis; CD26/DPPIV, Narrowband UVB, Pruritus, Psoriasis, Substance P

• Registration Number: TCTR20190709005
• Lead Sponsor: The National Research Council of Thailand

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-07-01
• Study Start: 2019-07-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

Inclusion criteria

•Patient aged ≥ 18 years old.

•Moderate to severe plaque-type psoriasis (Psoriasis Area and Severity Index; PASI >10) patient with pruritus.

Exclusion Criteria

Exclusion criteria

•Patients’ refusal to give a consent

•Patient taking other treatment for the disease; topical therapies within 2 weeks, systemic therapies and phototherapy within 4 weeks prior the study period.

•Patient with contraindication of narrowband UVB (e.g. xeroderma pigmentosum, other inherited disorder associated with UV-induced carcinogenesis, photodermatosis, history of skin cancer)

•Patient with known history of photosensitivity

•Presence of psoriasis arthritis

•Patient with CD26 and DPPIV associated diseases -T-cell leukemia/lymphoma, as Mycosis fungoides (MF) and Sezary syndrome (SS), Non-Hodgkin's lymphoma, T-cell large granular lymphocyte leukemia, Systemic lupus erythematosus, rheumatoid arthritis, Diabetes mellitus, cancer, chronic diseases, HIV infection , Allergic disease , Atopic dermatitis

• Patient with substance P associated diseases and drugs
oChronic urticarial, Prurigo nodularis, Major depressive disorder, anxiety, Uremia, Diabetic mellitus, Chronic pancreatitis, Coronary artery disease, Ulcerative colitis and Crohn's disease, Behçet's disease, Inflammatory bowel disease, Sickle cell crisis, Rheumatological diseases, Infectious diseases (such as AIDS and respiratory syncytial virus), Cancer, Autoimmune myelofibrosis, Liver diseases and Cirrhosis
oNicergoline, Chemotherapy, Hormone therapy, Etanercept, Anti-histamine, Tropisetron
•presence of autoimmune disease or immunocompromised conditions

•unreliable and poor compliance patients

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
serum levels of DPPIV/CD26 and truncated SP the laboratory process launch in one day, after no more than 1 month of serum storage ELISA KITs

Secondary Outcome Measures

Name	Time	Method
PASI score before and after irradiation PASI score,visaul analog scale (VAS) score and itch severity scale (ISS) before and after irradiation visaul analog scale (VAS) score and itch severity scale (ISS) ,The Dermatology life Quality Index (DLQI) before and after irradiation The Dermatology life Quality Index (DLQI)